ResearchMAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response
ResearchA Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2
ResearchGemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial
ResearchCD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer
ResearchA Phase 1 Trial of Low-dose Gemcitabine Combined with ATR Inhibitor Elimusertib for Advanced Solid Tumors
ResearchA model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma
ResearchA Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer
ResearchA Translational Study of the ATR Inhibitor Berzosertib as Monotherapy in Four Molecularly Defined Cohorts of Advanced Solid Tumors
ResearchCITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours
ResearchGeneration of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets
ResearchQuality indicators and patient outcome measures for palliative care in cancer patients: a systematic review
ResearchChemical Perturbations Impacting Histone Acetylation Govern Colorectal Cancer Differentiation